ARQT
Price
$25.80
Change
-$1.20 (-4.44%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
3.23B
26 days until earnings call
Intraday BUY SELL Signals
NUVL
Price
$123.70
Change
+$0.18 (+0.15%)
Updated
Jul 2, 04:59 PM (EDT)
Capitalization
9.79B
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ARQT vs NUVL

ARQT vs NUVL Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ARQT vs. NUVL commentary
Jul 05, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARQT is a Hold and NUVL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2026
Stock price -- (ARQT: $27.00 vs. NUVL: $123.52)
Brand notoriety: ARQT and NUVL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARQT: 171% vs. NUVL: 105%
Market capitalization -- ARQT: $3.23B vs. NUVL: $9.79B
ARQT [@Biotechnology] is valued at $3.23B. NUVL’s [@Biotechnology] market capitalization is $9.79B. The market cap for tickers in the [@Biotechnology] industry ranges from $134.02B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARQT’s FA Score shows that 0 FA rating(s) are green whileNUVL’s FA Score has 0 green FA rating(s).

  • ARQT’s FA Score: 0 green, 5 red.
  • NUVL’s FA Score: 0 green, 5 red.
According to our system of comparison, NUVL is a better buy in the long-term than ARQT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARQT’s TA Score shows that 6 TA indicator(s) are bullish while NUVL’s TA Score has 4 bullish TA indicator(s).

  • ARQT’s TA Score: 6 bullish, 3 bearish.
  • NUVL’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ARQT is a better buy in the short-term than NUVL.

Price Growth

ARQT (@Biotechnology) experienced а +1.16% price change this week, while NUVL (@Biotechnology) price change was -0.01% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.30%. For the same industry, the average monthly price growth was +5.93%, and the average quarterly price growth was +1921.84%.

Reported Earning Dates

ARQT is expected to report earnings on Jul 30, 2026.

NUVL is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Biotechnology (+2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NUVL($9.79B) has a higher market cap than ARQT($3.23B). NUVL YTD gains are higher at: 22.796 vs. ARQT (-7.025). ARQT has higher annual earnings (EBITDA): 14.3M vs. NUVL (-438.9M). NUVL has more cash in the bank: 1.29B vs. ARQT (224M). ARQT has higher revenues than NUVL: ARQT (416M) vs NUVL (0).
ARQTNUVLARQT / NUVL
Capitalization3.23B9.79B33%
EBITDA14.3M-438.9M-3%
Gain YTD-7.02522.796-31%
P/E RatioN/AN/A-
Revenue416M0-
Total Cash224M1.29B17%
Total Debt115MN/A-
FUNDAMENTALS RATINGS
ARQT: Fundamental Ratings
ARQT
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
PROFIT vs RISK RATING
1..100
98
SMR RATING
1..100
92
PRICE GROWTH RATING
1..100
39
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
49

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ARQTNUVL
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
76%
MACD
ODDS (%)
Bullish Trend 6 days ago
84%
Bearish Trend 3 days ago
77%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 19 days ago
83%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
N/A
Bearish Trend 9 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ARQT
Daily Signal:
Gain/Loss:
NUVL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FELV40.630.45
+1.12%
Fidelity Enhanced Large Cap Value ETF
GAA34.350.04
+0.10%
Cambria Global Asset Allocation ETF
GBAB14.33N/A
N/A
Guggenheim Taxable Municipal
SMYY7.11N/A
N/A
GraniteShares YieldBOOST SMCI ETF
LJUL23.85-0.01
-0.04%
Innovator Premium Income 15 Buf ETF -Jul

ARQT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARQT has been loosely correlated with XNCR. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ARQT jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARQT
1D Price
Change %
ARQT100%
N/A
XNCR - ARQT
43%
Loosely correlated
N/A
PCVX - ARQT
40%
Loosely correlated
N/A
SANA - ARQT
39%
Loosely correlated
N/A
NUVL - ARQT
39%
Loosely correlated
N/A
REGN - ARQT
39%
Loosely correlated
N/A
More

NUVL and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVL has been loosely correlated with MLTX. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVL jumps, then MLTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVL
1D Price
Change %
NUVL100%
N/A
MLTX - NUVL
49%
Loosely correlated
N/A
XNCR - NUVL
44%
Loosely correlated
N/A
PCVX - NUVL
42%
Loosely correlated
N/A
CLDX - NUVL
39%
Loosely correlated
N/A
GOSS - NUVL
39%
Loosely correlated
N/A
More